Citigroup Cuts Tandem Diabetes Care Price Target to 50.00

TNDM Stock  USD 35.15  2.38  6.34%   
About 53% of Tandem Diabetes' investor base is interested to short. The analysis of overall sentiment of trading Tandem Diabetes Care stock suggests that many investors are impartial at this time. Tandem Diabetes' investing sentiment overview a quick insight into current market opportunities from investing in Tandem Diabetes Care. Many technical investors use Tandem Diabetes Care stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Tandem Diabetes Care had its price objective lowered by Citigroup from 57.00 to 50.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the medical device companys stock. Citigroups price target indicates a potential upside of 45.48 percent from the companys current price. A

Read at thelincolnianonline.com
news
  

Tandem Diabetes Care Current Investor Sentiment

Panic Vs Confidence

47

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Tandem Diabetes' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Tandem Diabetes Care.

Tandem Diabetes Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tandem Diabetes can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tandem Diabetes Care Historical Investor Sentiment

Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes news discussions. The higher the estimate score, the more favorable the investor's outlook on Tandem Diabetes.

Tandem Diabetes Fundamental Analysis

We analyze Tandem Diabetes' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Profit Margin

Profit Margin Comparative Analysis

Tandem Diabetes is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Tandem Diabetes Care Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tandem Diabetes stock to make a market-neutral strategy. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics with similar companies.

Peers

Tandem Diabetes Related Equities

PACBPacific Biosciences   2.50   
0%
100.0%
ALGNAlign Technology   2.43   
0%
97.0%
INSPInspire Medical   2.21   
0%
88.0%
PODDInsulet   1.08   
0%
43.0%
MDTMedtronic PLC   1.06   
0%
42.0%
NNOXNano X   0.84   
0%
33.0%
PENPenumbra   0.53   
0%
21.0%
BSXBoston Scientific   0.50   
0%
20.0%
SYKStryker   0.43   
0%
17.0%
ABTAbbott Laboratories   0.38   
15.0%
0%
DXCMDexCom   0.54   
21.0%
0%
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(1.82)
Revenue Per Share
13.082
Quarterly Revenue Growth
0.314
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.